Stock Down Under

Money-Making Insights On

ASX-Listed Stocks

Find Us in

Stocks Down Under Analysts delve into a large variety of ASX-listed stocks and sectors.

Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years

By Nick Sundich | September 6, 2024

If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something to say about that. You see, any ‘treatments’ that exist are only about addressing the pain or other symptoms rather than being a cure or remission. These treatments tend to need frequent administration or lose…

Read More

Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017

By Nick Sundich | September 6, 2024

Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian Government’s Office of Drug Control in March 2017. During this time, there have been various busts and booms in the cannabis sector, although there has been little hype since the aftermath of TGA’s declassification of…

Read More

CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know

By Nick Sundich | September 6, 2024

In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it is important. And we’ll look at the Big 4 Banks‘ ratios.   So what is the CET1 ratio? A Common Equity Tier 1 (CET1) ratio is a measure of financial health and capital adequacy for…

Read More

Star Entertainment Group (ASX:SGR): Where to now in a post-COVID world? Can it avoid a looming cash crunch?

By Nick Sundich | September 5, 2024

In a July interview with the AFR, Star Entertainment Group boss Steve McCann admitted that his company’s pre-pandemic glory days were never coming back. Specifically, his company would never again see the huge flow of high-end international gamblers flock to its casinos, and would be relying on restaurants and hotels for revenue. We can’t fault…

Read More

Prescient Therapeutics (ASX:PTX): About to take the plunge into a Phase 2 trial against T-Cell Lymphoma

By Nick Sundich | September 5, 2024

There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation. The company is about to start Phase 2 for T-Cell Lymphoma and successful data here could suffice to appease the FDA without a Phase 3 trial, given the lack of treatment options currently available, but…

Read More

5 crucial things to look for in the annual report of an ASX company that may give you an advantage over other investors

By Nick Sundich | September 5, 2024

5 crucial things to look out for in the annual report of an ASX company! The ASX reporting season is not quite over yet. ASX companies have an additional month to file annual reports. Some may have already submitted their report and released it at the time of their annual results, while others may only…

Read More

Humm Group (ASX:HUM): Its no Big 4 Bank, but has defied the market in 2024

By Nick Sundich | September 4, 2024

Humm Group (ASX:HUM) has not had the year you might expect to a financier that is not either a Big 4 Bank or Macquarie (ASX:MQG). Interest rates appear to have peaked, and many financiers have not benefited as much as you might expect due to intense industry competition, as well as expectation that rates are…

Read More

Here are 5 ASX stocks at 12 month highs, and whether it is time to buy

By Nick Sundich | September 4, 2024

Here are 5 ASX stocks at 12 month highs!   Humm Group (ASX:HUM) Humm has been through a difficult few years. Obviously, as a company that offered BNPL services, it was been battered by the Tech Wreck of 2022 – albeit not as badly as other companies given Humm has a profitable consumer finance business,…

Read More

Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate

By Nick Sundich | September 3, 2024

It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common for biotech companies to change their name when they pivot to new indications and/or to new assets, but this was not the case with Percheron. It is still focused on Duchenne Muscular Dystrophy (DMD), a…

Read More

Underlying v Statutory results? There’s a big difference between the 2 – here’s how to tell

By Nick Sundich | September 3, 2024

When companies report results, you’ll hear underlying and statutory results. What is the difference between the two and how big does the gap tend to be?   The difference between underlying and statutory results (in theory) Underlying results refer to performance measures that strip out one-off charges or non-recurring events, providing a better representation of…

Read More

Sector Analysis

The-Best-Mining-Stocks

The Best Mining Stocks

Mining and resources stocks have substantial potential given demand for all types of resources and metals from gold and iron ore to battery metals like lithium and graphite! There are over 700 stocks in this sector from big miners to small cap explorers.

The-Best-Tech-Stocks

The Best Tech Stocks

Tech stocks are appetising in the context of an increasingly digital world ranging from data centre builders, cloud services providers and cybersecurity companies. Many of the ASX's best performing stocks in the last decade have been tech stocks.

The-Best-Uranium-Stocks

The Best Uranium Stocks

Uranium stocks are in a good spot right now with rising demand for clean energy, nuclear energy making a comeback and yellowcake pricing reaching levels not seen since the GFC. This has enabled many companies with mothballed projects to bring them out of hibernation.

Untitled design

The Best Healthcare Stocks

There are dozens of Healthcare stocks on the ASX ranging from big names like CSL and Cochlear with established products and markets, to small cap biotechs and medtechs hoping to follow in their footsteps and commercialise the next big innovation.

The-Best-Mining-Stocks

The Best Mining Stocks

The-Best-Tech-Stocks

The Best Tech Stocks

The-Best-Uranium-Stocks

The Best Uranium Stocks

Share Type Analysis

The Best ASX Stocks Right Now

The Best ASX Stocks Right Now

The quest for the best stocks to buy now is a never-ending one, but armed with a solid investment strategy, you can create a diversified portfolio that stands the test of time. We provide our Top 10 ASX stocks we think investors should consider right now. 

The Best ASX Stocks Right Now

The Best ASX Stocks Right Now

The Top Penny Stocks

The Top Penny Stocks

Navigating ASX Penny stocks, can be complex, given the diversity of companies operating in various sectors and the high risk associated with them. But there is potential for impressive returns if investors can find the right company.

The Top Penny Stocks

The Top Penny Stocks

The Top Dividend Stocks

The Top Dividend Stocks

Investing in Dividend stocks can provide an additional source of income, and so are popular with a wide variety of investors. But only some companies pay dividends, and even consistent payers can fluctuate payouts year to year. We outline the Top Dividend Stocks for investors to consider.

The Top Dividend Stocks

The Top Dividend Stocks

size set 1

Top ASX Index Funds

Explore our comprehensive analysis of the top ASX index funds, carefully curated by industry experts. Discover which funds are currently outperforming and why, based on detailed market trends and performance metrics. Ideal for both new and seasoned investors seeking strategic investment opportunities on the ASX. Dive into our report today to make informed investment decisions.

size set 1

Top ASX Index Funds

size 2

The Top Blue Chip Stocks

Discover the best ASX blue chip stocks for investment. Our industry experts provide in-depth analysis on these well-established companies with strong credit ratings and a long history of performance and stability. Explore market leaders like Commonwealth Bank of Australia, BHP Group Ltd, and National Australia Bank Limited.

size 2

The Top Blue Chip Stocks

size 3

Top ASX Growth Stocks for Investing

Explore our comprehensive analysis of the top ASX growth stocks for investing. Our industry experts have curated a detailed report on the most promising opportunities available in the market. Whether you're a seasoned investor or just starting out, our insights provide valuable information to help you make informed decisions.

size 3

Top ASX Growth Stocks for Investing

Webinars and Interviews

Weebit Nano (ASX:WBT) is on track for more commercial deals in 2024

  Weebit Nano (ASX:WBT) We spoke with Weebit Nano CEO, Coby Hanoch, about the A$1m in…

Actinogen Medical (ASX:ACW): Interview with CEO Dr Steve Gourlay

Actinogen Medical We talked with Dr Steve Gourlay, the CEO of Actinogen Medical (ASX:ACW), about the…

Chimeric Therapeutics (ASX:CHM): Solid prospects for licensing deals

  Chimeric Therapeutics (ASX:CHM) We spoke to Dr Rebecca McQualter, Chief Operating Officer of Chimeric Therapeutics…

BrainChip (ASX:BRN): Post AGM interview with CEO Sean Hehir

Interview with Sean Hehir, CEO of BrainChip (ASX:BRN) We spoke with Sean Hehir, CEO of BrainChip…

The Team Behind Stocks Down Under

1rw

Stuart Roberts

Co-Founder

Stuart Roberts is the co-founder of Stocks Down Under. Previously, Stuart covered the healthcare and biotechnology sectors at NDF Research and at stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015, where he developed a reputation for detailed analysis on previously uncovered Life Science companies. In 2018, he co-founded Pitt Street Research

Marc-circle-300x300_webp

Marc Kennis

Co-Founder

Marc is the co-founder of Stocks Down Under and has 25+ years experience analyzing companies in a range of sectors, including Food & Beverage, Industrials, Technology, Medical Equipment, Telecom and Media. Prior to moving to Australia in 2014, he worked for a number of brokers and banks in The Netherlands, including ING and Rabobank. In 2018, Marc co-founded Pitt Street Research,

The Team Behind Stocks Down Under

STUART ROBERTS

Stuart Roberts is the co-founder of Stocks Down Under. Previously, Stuart covered the healthcare and biotechnology sectors at NDF Research and at stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015, where he developed a reputation for detailed analysis on previously uncovered Life Science companies. In 2018, he co-founded Pitt Street Research together with Marc.

MARC KENNIS

Marc is the co-founder of Stocks Down Under and has 20+ years experience analyzing companies in a range of sectors, including Food & Beverage, Industrials, Technology, Medical Equipment, Telecom and Media. Prior to moving to Australia in 2014, he worked for a number of brokers and banks in The Netherlands, including ING and Rabobank. In 2018, Marc co-founded Pitt Street Research, Australia's preeminent issuer-sponsored equities research firm.

PETER KILBY

Pete is Stocks Down Under's head of customer service. He is an avid investor with a knack for deep-dive company research. Pete likes the more established companies on ASX, but doesn't shy away from the occasional risky play. At Stocks Down Under he gets to do the two things he loves most, investing and talking to like-minded people.

Please enter your name.
Please enter a message.